NCT03978624: A reported trial by UNC Lineberger Comprehensive Cancer Center
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03978624 |
|---|---|
| Title | Window of Opportunity Platform Study to Define Immunogenomic Changes With Pembrolizumab Alone and in Rational Combinations in Muscle-Invasive Bladder Cancer |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 23, 2020 |
| Completion date | March 25, 2024 |
| Required reporting date | March 25, 2027, midnight |
| Actual reporting date | Aug. 8, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |